BCL2 and Miyoshi myopathy: Functional profiling of BCL2 dependence can also predict clinical response in MM, as an alternative approach to precision medicine that utilizes preclinical BH3 profiling and ex vivo testing with venetoclax to determine what level of ex vivo drug sensitivity is associated with clinical response (115).